Nicola Casiraghi
University of Trento
PhosphorylationCancerInternal medicineOncologyExome sequencingAlleleChemistryDNA methylationImmunohistochemistryUbiquitinBiopsyProstateMultiple myelomaCancer biomarkersPTENDiseaseBone marrowContext (language use)CarfilzomibProstate cancerCirculating tumor DNATumor heterogeneityCastration resistantComputer scienceCancer researchPlasma protein bindingBioinformaticsAndrogen receptorComputational biologyMedicineBiologyMechanism (biology)
18Publications
7H-index
390Citations
Publications 16
Newest
#1Paolo GandelliniH-Index: 25
#2Nicola Casiraghi (University of Trento)H-Index: 7
Last. Nadia ZaffaroniH-Index: 66
view all 11 authors...
Source
#1Nicola Casiraghi (University of Trento)H-Index: 7
#2Francesco Orlando (University of Trento)H-Index: 1
Last. Alessandro Romanel (University of Trento)H-Index: 20
view all 10 authors...
MOTIVATION: The use of liquid biopsies for cancer patients enables the non-invasive tracking of treatment response and tumor dynamics through single or serial blood drawn tests. Next generation sequencing assays allow for the simultaneous interrogation of extended sets of somatic single nucleotide variants (SNVs) in circulating cell free DNA (cfDNA), a mixture of DNA molecules originating both from normal and tumor tissue cells. However, low circulating tumor DNA (ctDNA) fractions together with ...
Source
#1Himisha Beltran (Harvard University)H-Index: 56
#2Alessandro Romanel (University of Trento)H-Index: 20
Last. Francesca Demichelis (University of Trento)H-Index: 70
view all 19 authors...
Loss of androgen receptor (AR) signaling dependence occurs in approximately 15%-20% of advanced treatment-resistant prostate cancers, and this may manifest clinically as transformation from a prostate adenocarcinoma histology to a castration-resistant neuroendocrine prostate cancer (CRPC-NE). The diagnosis of CRPC-NE currently relies on a metastatic tumor biopsy, which is invasive for patients and sometimes challenging to diagnose due to morphologic heterogeneity. By studying whole-exome sequenc...
25 CitationsSource
#1Himisha Beltran (Harvard University)H-Index: 56
#2Alessandro Romanel (University of Trento)H-Index: 20
Last. Francesca Demichelis (University of Trento)H-Index: 70
view all 18 authors...
8Background: Loss of androgen receptor signaling dependence occurs in approximately 20% of treatment resistant prostate cancers, and this may manifest as transformation to castration resistant neur...
1 CitationsSource
#1Stephan M. Tirier (DKFZ: German Cancer Research Center)H-Index: 4
#2Jan-Philipp Mallm (DKFZ: German Cancer Research Center)H-Index: 22
Last. Marc S. Raab (DKFZ: German Cancer Research Center)H-Index: 8
view all 18 authors...
Source
#1Alexandra M. Poos (DKFZ: German Cancer Research Center)H-Index: 3
#2Jan-Philipp Mallm (DKFZ: German Cancer Research Center)H-Index: 22
Last. Niels Weinhold (University Hospital Heidelberg)H-Index: 1
view all 20 authors...
Source
#1Paolo GandelliniH-Index: 25
#2Nicola Casiraghi (University of Trento)H-Index: 7
Last. Nadia ZaffaroniH-Index: 66
view all 11 authors...
Abstract Background Genomic characterization of prostate cancer (PCa) biopsies may improve criteria for the selection of patients suitable for active surveillance (AS). Objective To identify somatic genomic aberrations associated with adverse outcome as AS protocol exclusion indicators. Design, setting and participants Whole-exome sequencing profiles were generated for Gleason score (GS) = 3 + 3 biopsies obtained from 54 PCa patients enrolled in two AS protocols. Patients were selected as repres...
1 CitationsSource
#1Daniel Nava Rodrigues (ICR: Institute of Cancer Research)H-Index: 33
#2Nicola Casiraghi (University of Trento)H-Index: 7
Last. Johann S. de Bono (ICR: Institute of Cancer Research)H-Index: 124
view all 20 authors...
Purpose: Metastatic castration resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments. Intra-patient genomic heterogeneity could be a contributing factor to this clinical heterogeneity. Here we used whole-genome sequencing (WGS) to investigate genomic heterogeneity in 21 previously treated CRPC metastases from 10 patients to investigate intra-patient molecular heterogeneity (IPMH). Experime...
17 CitationsSource
#1Nicola CasiraghiH-Index: 7
Prostate cancer is a highly heterogeneous disease and its manifestations can vary from indolent localized tumor to widespread metastases. This heterogeneity is also observed at the molecular level both inter- and intra-patient. Intra-patient heterogeneity in the clinical setting of men with castration resistant prostate cancer (CRPC) might be informative in terms of treatment decision. Here I present analytical work on two approaches relevant to the characterization of intra-patient heterogeneit...
Source